{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:45:25Z","timestamp":1790379925192,"version":"4.1.0"},"reference-count":55,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2018,3,14]],"date-time":"2018-03-14T00:00:00Z","timestamp":1520985600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J cachexia sarcopenia muscle"],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In 1993, megestrol acetate (MA) was approved by the US Food and Drug Administration for the treatment of anorexia, cachexia, or unexplained weight loss in patients with acquired immunodeficiency syndrome. The mechanism by which MA increases appetite is unknown, and its effectiveness for anorexia and cachexia in neoplastic, elderly, and acquired immunodeficiency syndrome patients is under investigation. This is an updated version of a Cochrane systematic review first published in 2005 and later updated in 2013 entitled \u2018Megestrol acetate for the treatment of anorexia\u2013cachexia syndrome\u2019. MA vs. placebo: in studies where MA was compared with placebo, the overall results showed that MA patients gained weight (mean difference, MD 2.25\u00a0kg, 95% CI [1.19, 3.3]) but did not gain quality of life (QOL) (standarized mean difference, SMD 0.5, 95% CI [\u22120.13, 1.13]), with more adverse events (relative risk, RR 1.46, 95% CI [1.05, 2.04]), but no difference in deaths (RR 1.26, 95% CI [0.70, 2.27]). MA vs. no treatment: MA patients gained weight (MD 1.45\u00a0kg, 95% CI [0.15, 2.75]) but did not gain QOL (standardized mean difference 3.89 95% CI [\u221214, 6.28]). There was no increase in adverse events (RR 0.90, 95% CI [0.39, 2.08]) or deaths (RR 1.01, 95% CI [0.42, 2.45]). MA vs. active drugs: MA patients gained weight (MD 2.5\u00a0kg, 95% CI [0.37, 4.64]) but did not gain QOL (MD 0.20 95% CI [\u22120.02, 0.43]) and did not report an increase in adverse events (RR 1.05 95% CI [0.95, 1.16]) or in deaths (RR 1.53, 95% CI [1.02, 2.29]) Different doses of MA: in studies where lower doses of MA were compared with higher doses of MA, we did not find differences either in weight gain (MD \u22120.94\u00a0kg, 95% CI [\u22123.33, 1.45]), QOL (MD 0.31 95% CI [\u22120.19, 0.81]), or adverse events (RR 1.34, 95% CI [0.65, 2.76]). Thus, we cannot reach a conclusion for an optimal dose of MA.<\/jats:p>","DOI":"10.1002\/jcsm.12292","type":"journal-article","created":{"date-parts":[[2018,3,15]],"date-time":"2018-03-15T08:25:52Z","timestamp":1521102352000},"page":"444-452","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":81,"title":["Megestrol acetate for cachexia\u2013anorexia syndrome. A systematic review"],"prefix":"10.1002","volume":"9","author":[{"given":"Vicente","family":"Ruiz\u2010Garc\u00eda","sequence":"first","affiliation":[{"name":"Hospital at Home Unit, Tower C, Floor 1 Office 5 La Fe University Hospital  Valencia Spain &amp; CASPe Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"L\u00f3pez\u2010Briz","sequence":"additional","affiliation":[{"name":"Department of Pharmacy La Fe University Hospital  Valencia Spain, &amp; CASPe Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Carbonell\u2010Sanchis","sequence":"additional","affiliation":[{"name":"ENT Department Sagunto Hospital  Sagunto Spain, &amp; CASPe Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Bort\u2010Mart\u00ed","sequence":"additional","affiliation":[{"name":"Acella Incubator  Paterna Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Gonz\u00e1lvez\u2010Perales","sequence":"additional","affiliation":[{"name":"National Health Service  Algemes\u00ed Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,3,14]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004310"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004310.pub2"},{"key":"e_1_2_11_4_1","first-page":"CD004310","article-title":"Megestrol acetate for treatment of anorexia\u2010cachexia syndrome","volume":"3","author":"Ruiz Garcia V","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.1.213"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/3.suppl_3.S25"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/1098-1128(200101)21:1<83::AID-MED4>3.0.CO;2-1"},{"key":"e_1_2_11_8_1","first-page":"1049","article-title":"Anorexia\/cachexia in patients with HIV: lessons for the oncologist","volume":"10","author":"Von Roenn JH","year":"1996","journal-title":"Oncology"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13539-014-0164-8"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.12059"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2605.2001.00291.x"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008291825695"},{"key":"e_1_2_11_13_1","volume-title":"Estudio de Fase II Randomizado de Dos Niveles Posol\u00f3gicos de Acetato de Megestrol versus PLacebo para el Tratamiento de la Anorexia y la Caquexia en Pacientes con C\u00e1ncer Locoregional Avanzado o Metast\u00e1sico","author":"Casado Herr\u00e1ez A","year":"2008"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(98)00219-6"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1067\/mpd.2002.121936"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-199210000-00008"},{"key":"e_1_2_11_17_1","first-page":"162","article-title":"Supportive treatment with megestrol acetate during radio\u2010(chemo\u2010)therapy. A randomized trial","volume":"172","author":"Fietkau R","year":"1996","journal-title":"Strahlenther Onkol"},{"key":"e_1_2_11_18_1","first-page":"72","article-title":"Megestrol acetate prevents cachexia in elderly cancer patient","volume":"9","author":"Gambardella A","year":"1998","journal-title":"Ann Oncol"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1996.297"},{"key":"e_1_2_11_20_1","first-page":"20","article-title":"Changes of nutritional and psychological status after megestrol acetate treatment of cancer cachexia","volume":"15","author":"Giacosa A","year":"1997","journal-title":"Riv Ital Nutr Parenter Ed Enterale"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1159\/000227125"},{"key":"e_1_2_11_22_1","first-page":"193","article-title":"Low doses of megestrol acetate increase weight and improve nutrition status in patients with severe chronic obstructive pulmonary disease and weight loss","volume":"137","author":"Herrejon A","year":"2011","journal-title":"Med Clin Barc"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.2.567"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.06.024"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/82.13.1127"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1159\/000227407"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.10.3299"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/0169-5002(94)94107-6"},{"key":"e_1_2_11_29_1","first-page":"S57","article-title":"A randomized phase III clinical trial of a combined treatment with megestrol acetate+carnitine+celecoxib+antioxidants vs. megestrol acetate alone for patients with cancer cachexia syndrome","volume":"20","author":"Madeddu C","year":"2012","journal-title":"Support Care Cancer"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/0261-5614(94)90065-5"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1086\/381977"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-121-6-199409150-00002"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(93)91762-A"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1159\/000227127"},{"key":"e_1_2_11_35_1","first-page":"32","article-title":"Megestrol acetate in cancer cachexia","volume":"18","author":"Schmoll E","year":"1991","journal-title":"Semin Oncol"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1177\/095646249200300409"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.2820690532"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.1997.13.305"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1177\/030089160208800406"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-199808000-00006"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1159\/000227411"},{"key":"e_1_2_11_42_1","first-page":"206","article-title":"Safety and efficacy of two preparations of megestrol acetate in HIV\u2010infected individuals with weight loss in Africa, India, and the United States","volume":"7","author":"Wanke C","year":"2007","journal-title":"J Appl Res"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.121.4.1070"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2000.tb04993.x"},{"key":"e_1_2_11_45_1","first-page":"227","article-title":"Palliative treatment of cancer anorexia with oral suspension of megestrol acetate","volume":"50","author":"Tom\u00edska M","year":"2003","journal-title":"Neoplasma"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24828"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1177\/030089161309900218"},{"key":"e_1_2_11_48_1","volume-title":"Study to Evaluate the Effect of Megestrol Acetate in Weight Loss in Dementia Patients","author":"Sanchez P."},{"key":"e_1_2_11_49_1","unstructured":"CurrowD.Randomised double blind control trial of megestrol acetate dexamethasone and placebo in the management of anorexia in people with cancer. Https:\/\/Www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?ACTRN=126080004053142008."},{"key":"e_1_2_11_50_1","first-page":"691","article-title":"A Phase III randomized study comparing the effects of oxandrolone (Ox) and megestrol acetate (Meg) on weight (wt), lean body mass (LBM) and quality of life (QOL) in solid tumor patients (pts) receiving chemotherapy (chemo) [abstract]","volume":"24","author":"Lesser GJ","year":"2006","journal-title":"J Clin Oncol ASCO Annu Meet Proc"},{"key":"e_1_2_11_51_1","unstructured":"Anonymous.A study of megestrol acetate in HIV\u2010infected childrenn.d.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00002182(accessed September 10 2017)."},{"key":"e_1_2_11_52_1","unstructured":"HaydenJ.Randomized placebo\u2010controlled study of aerobic exercise and resistance training plus megestrol acetate for hiv\u2010wasting \u2010 Full text view\u2010clinicaltrials.govn.d.https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00004664(accessed September 10 2017)."},{"key":"e_1_2_11_53_1","unstructured":"GrevenKM.Megestrol to limit weight loss and improve quality of life in treating patients with head and neck cancern.d.https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT00006799(accessed September 10 2017)."},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.12035"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.12116"},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.12089"}],"container-title":["Journal of Cachexia, Sarcopenia and Muscle"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcsm.12292","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcsm.12292","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T12:07:44Z","timestamp":1695470864000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jcsm.12292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,14]]},"references-count":55,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["10.1002\/jcsm.12292"],"URL":"https:\/\/doi.org\/10.1002\/jcsm.12292","archive":["Portico"],"relation":{},"ISSN":["2190-5991","2190-6009"],"issn-type":[{"value":"2190-5991","type":"print"},{"value":"2190-6009","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,14]]},"assertion":[{"value":"2017-07-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-01-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}